Skip to main content
Journal cover image

Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model.

Publication ,  Journal Article
Hong, H; Dowdy, DW; Dooley, KE; Francis, HW; Budhathoki, C; Han, H-R; Farley, JE
Published in: Clin Infect Dis
February 14, 2020

BACKGROUND: Individuals treated for drug-resistant tuberculosis (DR-TB) with aminoglycosides (AGs) in resource-limited settings often experience permanent hearing loss, yet there is no practical method to identify those at higher risk. We sought to develop a clinical prediction model of AG-induced hearing loss among patients initiating DR-TB treatment in South Africa. METHODS: Using nested, prospective data from a cohort of 379 South African adults being treated for confirmed DR-TB with AG-based regimens we developed the prediction model using multiple logistic regression. Predictors were collected from clinical, audiological, and laboratory evaluations conducted at the initiation of DR-TB treatment. The outcome of AG-induced hearing loss was identified from audiometric and clinical evaluation by a worsened hearing threshold compared with baseline during the 6-month intensive phase. RESULTS: Sixty-three percent of participants (n = 238) developed any level of hearing loss. The model predicting hearing loss at frequencies from 250 to 8000 Hz included weekly AG dose, human immunodeficiency virus status with CD4 count, age, serum albumin, body mass index, and pre-existing hearing loss. This model demonstrated reasonable discrimination (area under the receiver operating characteristic curve [AUC] = 0.71) and calibration (χ2[8] = 6.10, P = .636). Using a cutoff of 80% predicted probability of hearing loss, the positive predictive value of this model was 83% and negative predictive value was 40%. Model discrimination was similar for ultrahigh-frequency hearing loss (frequencies >9000 Hz; AUC = 0.81) but weaker for clinically determined hearing loss (AUC = 0.60). CONCLUSIONS: This model may identify patients with DR-TB who are at highest risk of developing AG-induced ototoxicity and may help prioritize patients for AG-sparing regimens in clinical settings where access is limited.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

February 14, 2020

Volume

70

Issue

5

Start / End Page

917 / 924

Location

United States

Related Subject Headings

  • Tuberculosis, Multidrug-Resistant
  • South Africa
  • Prospective Studies
  • Microbiology
  • Humans
  • Hearing Loss
  • Aminoglycosides
  • Adult
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hong, H., Dowdy, D. W., Dooley, K. E., Francis, H. W., Budhathoki, C., Han, H.-R., & Farley, J. E. (2020). Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. Clin Infect Dis, 70(5), 917–924. https://doi.org/10.1093/cid/ciz289
Hong, Hyejeong, David W. Dowdy, Kelly E. Dooley, Howard W. Francis, Chakra Budhathoki, Hae-Ra Han, and Jason E. Farley. “Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model.Clin Infect Dis 70, no. 5 (February 14, 2020): 917–24. https://doi.org/10.1093/cid/ciz289.
Hong H, Dowdy DW, Dooley KE, Francis HW, Budhathoki C, Han H-R, et al. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. Clin Infect Dis. 2020 Feb 14;70(5):917–24.
Hong, Hyejeong, et al. “Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model.Clin Infect Dis, vol. 70, no. 5, Feb. 2020, pp. 917–24. Pubmed, doi:10.1093/cid/ciz289.
Hong H, Dowdy DW, Dooley KE, Francis HW, Budhathoki C, Han H-R, Farley JE. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model. Clin Infect Dis. 2020 Feb 14;70(5):917–924.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

February 14, 2020

Volume

70

Issue

5

Start / End Page

917 / 924

Location

United States

Related Subject Headings

  • Tuberculosis, Multidrug-Resistant
  • South Africa
  • Prospective Studies
  • Microbiology
  • Humans
  • Hearing Loss
  • Aminoglycosides
  • Adult
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences